Europe Antibody Discovery Market By Offering, Technology, And Country - Analysis And Forecast, 2025-2035 AI And Automation Drive 12.11% CAGR And A $10.13 Billion Opportunity

(MENAFN- GlobeNewsWire - Nasdaq) Boost ROI through AI-enabled discovery, specialized CRO outsourcing, pipeline optimization, advanced antibody formats, strategic partnerships, licensing and targeted market entry.

Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Europe Antibody Discovery Market: Focus on Offering, Technology, and Country - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.

The Europe antibody discovery market is projected to grow from $3.23 billion in 2025 to $10.13 billion by 2035, registering a CAGR of 12.11% during the forecast period 2025-2035. Market expansion is supported by Europe's established biomedical research ecosystem, advanced healthcare infrastructure, leading academic institutions, and growing community of biotechnology and pharmaceutical companies.

Demand for targeted and precision therapeutics is driving continued investment in antibody discovery for oncology, autoimmune diseases, infectious diseases, chronic conditions, and rare disorders. The increasing use of fully human and humanized antibodies reflects the industry's focus on specificity, safety, reduced immunogenicity, and improved clinical outcomes.

Technology innovation remains central to the development of the Europe antibody discovery market. Phage display, hybridoma technology, single B-cell technologies, transgenic animal-based methods, and glycoengineering are supporting the identification and optimization of therapeutic candidates. These platforms are increasingly integrated with automation, high-throughput screening, next-generation sequencing, microfluidics, computational biology, and advanced translational assays.

Artificial intelligence and machine learning are also gaining importance across target identification, antibody design, affinity maturation, developability assessment, and lead optimization. The adoption of AI-driven modeling can shorten discovery timelines and improve candidate selection, although progress remains dependent on access to standardized, high-quality datasets and robust validation frameworks.

Innovation in next-generation antibody formats is expanding the market's therapeutic potential. Bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, single-domain antibodies, and engineered antibody fragments are attracting investment as companies pursue differentiated treatment strategies. Integrated end-to-end platforms that combine wet-lab screening, computational analysis, and disease-relevant models are also becoming more prominent.

Market Segmentation

By Offering

• Product
• Services

By Technology

• Phage Display Technology
• Hybridoma Technology
• Single B-Cell Technologies
• Transgenic Animal-based Methods
• Other Technologies

By Region

• Europe

Europe Antibody Discovery Market Trends

• Accelerated adoption of AI and machine learning for target identification, antibody design, and lead optimization.
• Growing development of bispecific antibodies, antibody-drug conjugates, nanobodies, and engineered fragments.
• Expansion of integrated discovery platforms combining laboratory screening with computational biology.
• Increased use of function-first, cell-based, and disease-relevant screening models.
• Greater reliance on contract research organizations and specialist service providers for discovery and early development.

Key Market Drivers

• Sustained demand for targeted biologics across oncology, autoimmune disorders, chronic diseases, infectious diseases, and rare conditions.
• Increasing pharmaceutical R&D expenditure and venture funding for antibody-focused biotechnology companies.
• Advances in single-cell analysis, sequencing, high-throughput screening, automation, and microfluidics.
• Productivity and cost pressures encouraging outsourcing and platform-based discovery models.
• Supportive regulatory frameworks for biologics and precision medicine across major European markets.

Academic-industry collaborations and partnerships among pharmaceutical companies, biotechnology firms, research institutions, and contract research organizations are strengthening regional capabilities. Outsourcing provides access to specialized expertise, flexible capacity, and scalable infrastructure while helping companies manage development costs and accelerate early-stage programs.

Major Market Challenges

• Limited availability of standardized datasets for training and validating AI-driven discovery models.
• High capital and operating costs associated with advanced platforms, automation, and digital infrastructure.
• Uncertainty surrounding intellectual property ownership for AI-designed antibodies and shared datasets.
• Regulatory ambiguity related to validation, reproducibility, and approval pathways for AI-enabled outputs.
• Fragmentation among service providers and technology platforms, complicating vendor selection and performance benchmarking.
• Competitive pressure from gene therapies, cell therapies, and other emerging treatment modalities.

Strategic Value of the Market Report

Product and Innovation: The report identifies high-value opportunities across antibody discovery platforms, engineering technologies, service models, and therapeutic applications. It supports R&D planning, technology adoption, pipeline prioritization, candidate validation, and lead optimization strategies.

Growth and Marketing: Analysis of regional adoption patterns, investment activity, regulatory conditions, and partnership opportunities can support market entry and commercialization planning. Organizations can use these insights to refine licensing, collaboration, positioning, and customer engagement strategies across key offering, technology, application, and end-user segments.

Competitive Intelligence: Company profiling and benchmarking provide visibility into strategic collaborations, funding, mergers, acquisitions, research priorities, and technology adoption. This intelligence enables stakeholders to identify market gaps, anticipate competitive shifts, differentiate their capabilities, and strengthen their position within the Europe antibody discovery ecosystem.

Key Attributes:

Report Attribute	Details
No. of Pages	75
Forecast Period	2025 - 2035
Estimated Market Value (USD) in 2025	$3.23 Billion
Forecasted Market Value (USD) by 2035	$10.13 Billion
Compound Annual Growth Rate	12.1%
Regions Covered	Europe

Key Topics Covered:
Executive Summary
Scope and Definition
1 Market: Industry Outlook
1.1 Regulatory Landscape / Compliance
1.1.1 E.U.
1.1.1.1 Germany
1.1.1.2 France
1.1.1.3 Italy
1.2 Pricing Analysis
1.2.1 By Product
1.2.2 By Region
1.3 Supply Chain Analysis
1.4 Value Chain Analysis
1.5 Patent Analysis
1.5.1 By Country
1.5.2 By Company
1.6 Market Dynamics
1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
1.6.2 Market Trends
1.6.2.1 Shift toward Fully Human and Humanized Antibodies
1.6.2.2 Increasing Reliance on High-Throughput Screening and Automation
1.6.2.3 Growing Role of Contract Research Organizations (CROs)
1.6.3 Market Drivers
1.6.3.1 Advancements in Antibody Engineering for Therapeutic Applications
1.6.3.2 Increasing Prevalence of Chronic Diseases
1.6.4 Market Challenges
1.6.4.1 Rising Shift Toward Alternative Antibody-Based Treatment Modalities
1.6.4.2 High Costs Restrict Widespread Adoption of Antibody Therapies
1.6.5 Market Opportunities
1.6.5.1 Integration of Artificial Intelligence and Machine Learning in Antibody Discovery
2 Region
2.1 Regional Summary
2.2 Europe
2.2.1 Regional Overview
2.2.2 Driving Factors for Market Growth
2.2.3 Factors Challenging the Market
2.2.4 By Offering
2.2.5 By Technology
2.2.6 By Country
2.2.6.1 U.K.
2.2.6.1.1 By Offering
2.2.6.1.2 By Technology
2.2.6.2 Germany
2.2.6.2.1 By Offering
2.2.6.2.2 By Technology
2.2.6.3 France
2.2.6.3.1 By Offering
2.2.6.3.2 By Technology
2.2.6.4 Italy
2.2.6.4.1 By Offering
2.2.6.4.2 By Technology
2.2.6.5 Spain
2.2.6.5.1 By Offering
2.2.6.5.2 By Technology
2.2.6.6 Sweden
2.2.6.6.1 By Offering
2.2.6.6.2 By Technology
2.2.6.7 Netherlands
2.2.6.7.1 By Offering
2.2.6.7.2 By Technology
2.2.6.8 Rest-of-Europe
2.2.6.8.1 By Offering
2.2.6.8.2 By Technology
3 Markets - Competitive Benchmarking & Company Profiles
3.1 Product Mapping
3.1.1 By Company
3.1.2 By Offering
3.1.3 By Technology
3.2 Pipeline Analysis
3.3 Company Profiles
3.3.1 Genmab A/S
3.3.1.1 Overview
3.3.1.2 Top Products/Product Portfolio
3.3.1.3 Top Competitors
3.3.1.4 Target Customers
3.3.1.5 Key Personnel
3.3.1.6 Analyst View
4 Research Methodology
4.1 Data Sources
4.1.1 Primary Data Sources
4.1.2 Secondary Data Sources
4.1.3 Data Triangulation
4.2 Market Estimation and Forecast
List of Figures [20]
List of Tables [24]
Companies Featured

• Genmab A/S

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01102026004107003653ID1111743909